Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

NCT00103194 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

NIH

Sponsor class

Conditions

Recurrent Prostate Cancer
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer

Interventions

DRUG: lapatinib ditosylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)